Search

Displaying results 4611 - 4620 of 10000 in total
  1. Drug

    NV-18

    go.drugbank.com/drugs/DB05886
    Experimental

    Like phenoxodiol, NV-18 is broadly effective in the laboratory against almost all human cancer types, but NV-18 is distinctive in showing particular potency against melanoma and cholangiocarcinoma (cancer

  2. Drug

    PSN357

    go.drugbank.com/drugs/DB05044
    Experimental

    PSN357 is a glycogen phosphorylase inhibitor (GPI), which is designed to rapidly lower blood glucose levels by preventing glycogen breakdown to glucose in the liver.

  3. Drug

    Imazaquin

    go.drugbank.com/drugs/DB04582
    Experimental

    Categories: Compounds used in a research, industrial, or household setting
  4. Drug

    2,5-di-tert-butylhydroquinone

    go.drugbank.com/drugs/DB04638
    Experimental

    Categories: Compounds used in a research, industrial, or household setting
  5. Drug

    Dextranomer

    go.drugbank.com/drugs/DB13560
    Investigational

    Categories: Compounds used in a research, industrial, or household setting
  6. Drug

    Famphur

    go.drugbank.com/drugs/DB11408
    ExperimentalVet approved

    Categories: Compounds used in a research, industrial, or household setting
  7. Drug

    TAFA-93

    go.drugbank.com/drugs/DB05887
    Experimental

    TAFA93 is a novel prodrug of the mTOR inhibitor rapamycin which has successfully completed Phase 1 clinical development. mTOR inhibitors are currently used in the prevention of organ rejection in transplantation

  8. Drug

    Carbenicillin

    go.drugbank.com/drugs/DB00578
    Approved

    Broad-spectrum semisynthetic penicillin derivative used parenterally. It is susceptible to gastric juice and penicillinase and may damage platelet function.

    Synonyms: N-(2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)hept-6-yl)-2-phenylmalonamic acid
  9. Drug

    Lucanthone

    go.drugbank.com/drugs/DB04967
    Investigational

    (From Martindale The Extrapharmacopoeia, 30th ed., p46). It is currently being tested as a radiation sensitizer.

  10. Drug

    Nirogacestat

    go.drugbank.com/drugs/DB12005
    ApprovedInvestigational

    Desmoid tumors are typically characterized by aberrant activation in Notch signaling. … It was previously granted breakthrough therapy, fast track, and orphan drug designations for the treatment of desmoid tumors, and the final approval was based on positive results obtained in the Phase